Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NRX Pharmaceuticals ( (NRXP) ) has issued an update.
On December 2, 2025, NRx Pharmaceuticals announced it had repaid the remaining $5.4 million owed to Anson Funds, LLC via a conversion of debt into common stock, a transaction completed without additional warrants or repricing mechanisms, after Anson had originally lent $16.2 million to refinance prior loans and support operating expenses. The move leaves NRx expecting to end 2025 with a debt-free balance sheet, a shift the company says strengthens its capital structure and positions it to pursue accelerated growth in 2026 as it seeks potential drug approvals and clinic expansions for its CNS therapies targeting suicidal depression and PTSD, with implications for reduced financial risk and greater strategic flexibility for investors and partners.
The most recent analyst rating on (NRXP) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NRX Pharmaceuticals stock, see the NRXP Stock Forecast page.
Spark’s Take on NRXP Stock
According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.
NRX Pharmaceuticals is navigating significant financial hurdles with net losses and negative equity, typical for early-stage biotech firms. However, strategic initiatives and drug development progress provide potential upside. Technical analysis and valuation reflect speculative potential, with the stock currently exhibiting mixed technical signals. The positive outlook from the earnings call highlights strategic moves that could improve the company’s financial health if successful.
To see Spark’s full report on NRXP stock, click here.
More about NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company focused on developing NMDA-based therapeutics for central nervous system disorders, including suicidal depression, chronic pain and PTSD. Its pipeline includes NRX-100, a preservative-free intravenous ketamine that has received Fast Track designation for treating suicidal ideation in depression, and NRX-101, an oral D-cycloserine/lurasidone combination granted Breakthrough Therapy designation for suicidal bipolar depression; the company is advancing regulatory filings for NRX-100, including an ANDA re-filing and a New Drug Application.
Average Trading Volume: 473,463
Technical Sentiment Signal: Sell
Current Market Cap: $75.79M
See more insights into NRXP stock on TipRanks’ Stock Analysis page.